We offer five, integrated discovery platforms for screening and lead identification of bispecific and multispecific antibody approaches. Novel platforms include our WuXiBody TM , SDArBody TM , SKYBody TM , and Ligand’s OmniFlic®. We also offer a standard bispecific engineering platform utilizing technologies available in the public domain. Based on your R&D goals, we can offer many different bsAb and msAb platforms and formats that best suit your biology and drug development requirements. Bispecific & Multispecific Antibody Generation
Leading Proprietary Bispecific Platform
VHH-based Multispecific Ab Platform
Transgenic Rats with Common Light Chain
Proprietary Platform for bsAbs Generated Using scFv
WuXi Biologics General Platform
Other Molecular Modalities
Extensive design, generation and discovery of new molecular modalities is available, including but not limited to: Antibody Drug Conjugates (ADCs), recombinant proteins, fusion proteins, cytokines, immunocytokines, peptides, nanobodies, antibody fragments, TCR-based antibodies, virus proteins, and other biologics.
Lead Optimization & Characterization
In Vitro Lead Characterization
Lead Optimization
WuXi Biologics offers extensive lead assessment and optimization services for antibody therapeutics. Services include humanization, affinity maturation, Fc engineering and post translational modification (PTM) optimization.
Comprehensive biologics screening and characterization throughout the lead drug candidate selection process is provided and we offer assay development services as required for your specific lead characterization needs. Capabilities include:
Humanization A inity Maturation Fc Engineering
• Affinity by SPR (Surface Plasmon Resonance) • Bispecific antibody simultaneous binding • Related SPR service • Peptide mapping (linear epitope) • Domain mapping (domain epitope) • Alanine Scanning Mutagenesis (both linear and conformational epitopes)
Binding
Epitope Binning and Mapping
Sequence Analysis Structure Modeling PTM Optimization Functional Comparison
Functional Assays
• Biochemical Assays • Cellular Assays
In Vivo Lead Characterization
Our senior scientists and experts, many trained in the U.S. and Europe provide the full-spectrum of in vivo characterization services including in vivo efficacy evaluation of therapeutic antibodies, ADCs, CAR-T products, and other large molecules for the treatment of tumors, autoimmune conditions, inflammatory disease, diabetes and other diseases. We also provide high-quality preclinical PK, safety, exploratory toxicology, biomarker and ex vivo studies to support pharmaceutical companies worldwide. The efficacy characterization services at WuXi Biologics involve the use of hundreds of models across many disease states for lead screening and characterization purposes. The table below gives just a few examples of the multitude of models available at WuXi Biologics.
Tumor Models
Autoimmune Disease Models
Metabolic Disease Models
GVHD Models
• Syngeneic • CDX
• Autoimmune Encephalomyelitis (EAE) • Rheumatoid Arthritis (RA) • Asthma Model • Systemic Lupus Erythematosus (SLE) • Intestinal Bowel Disease Model (IBD) • Air pouch Model • Atopic Dermatitis (AD) and Psoriasis model
• Oral glucose tolerance test (OGTT) model • Diet-induced obesity (DIO) model in C57BL/6 • HFMCD diet-induced NASH in C57BL/6 • mFc.hGDF15-induced Body weight loss in BALB/c
Graft-versus-host disease model in B-NDG
• Human PBMC • Knock-in (KI) • Human CD34 Stem Cell Models
Powered by FlippingBook